Association between 1,5-anhydro-D-sorbitol, Insulin, and Incretins in Patients with Pre-diabetes and ST-elevation Myocardial Infarction
DOI:
https://doi.org/10.3889/oamjms.2022.8788Keywords:
Insulin, Glucagon/GLP-1, Prediabetes, 1,5-AG, ST-elevation myocardial infarctionAbstract
BACKGROUND: Prediabetes itself could be an independent predictor of such adverse cardiovascular events as myocardial infarction and ischemic stroke. Since prediabetes is linked with hyperinsulinism it could also cause fluctuations of incretins concentration. Another significant fact related to prediabetes is glycemic variability. The impact of these factors on prediabetes and acute myocardial infarction is a promising phenomenon to study.
AIM: The study aims to estimate insulin, incretins, and glycemic variability in patients with impaired carbohydrate metabolism and acute myocardial infarction
METHODS: The 255 prediabetes patients participated in the observational case-control study. The first group included 85 patients hospitalized for STEMI. The second group included 170 patients without STEMI. Insulin and incretins were measured using a multiplex immunological assay with XMap technology on Bioplex 3D. The high-performance liquid chromatography with mass spectrometry was used to evaluate 1,5-AG concentration. The binary logistic regression was performed to evaluate the association between studying parameters and STEMI.
RESULTS: The insulin secretion parameters showed higher insulin and C-peptide level in patients with STEMI. A similar trend was noted for the HOMA-IR index. Among incretin, we revealed a higher level of glucagon and reduced GLP-1 in patients with STEMI. The of 1,5-AG in STEMI patients was significantly lower than in non-STEMI patients. The logistic regression model shows that a lower plasma concentration of 1,5-AG increases the odds of STEMI in patients with prediabetes [OR 2.304 (95% CI 1.980–2.973), p = 0.018]. Reduced GLP-1 concentration also increased the odds of STEMI [OR 1.775 (95% CI 1.460-1.990), p = 0.001].
CONCLUSION: We discovered the association between 1,5-AG, GLP-1, and STEMI in patients with prediabetes. It is designating their potential role as cardiovascular risk markers in non-diabetic patients with impaired glucose metabolism.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
World Health Organization. Global Status Report on Noncommunicable Diseases. Geneva, Switzerland: World Health Organization; 2016.
Zhang P, Zhang X, Brown J, Vistisen D, Sicree R, Shaw J, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(3):293-301. https://doi.org/10.1016/j.diabres.2010.01.026 PMid:20171754 DOI: https://doi.org/10.1016/j.diabres.2010.01.026
Cai X, Zhang Y, Li M, Wu JH, Mai L, Li J, et al. Association between prediabetes and risk of all-cause mortality and cardiovascular disease: Updated meta-analysis. BMJ. 2020;370:m2297. https://doi.org/10.1136/bmj.m2297 PMid:32669282 DOI: https://doi.org/10.1136/bmj.m2297
Khetan AK, Rajagopalan S. Prediabetes. Can J Cardiol. 2018;34(5):615-23. https://doi.org/10.1016/j.cjca.2017.12.030 PMid:29731022 DOI: https://doi.org/10.1016/j.cjca.2017.12.030
Williams R, Karuranga S, Malanda B, Saeedi P, Basit A, Besançon S, et al. Global and regional estimates and projections of diabetes-related health expenditure: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2020;162:108072. https://doi.org/10.1016/j.diabres.2020.108072 PMid:32061820 DOI: https://doi.org/10.1016/j.diabres.2020.108072
Freckmann G, Hagenlocher S, Baumstark A, Jendrike N, Gillen RC, Rössner K, et al. Continuous glucose profiles in healthy subjects under everyday life conditions and after different meals. J Diabetes Sci Technol. 2007;1(5):695-703. https://doi.org/10.1177/193229680700100513 PMid:19885137 DOI: https://doi.org/10.1177/193229680700100513
Selvin E, Warren B, He X, Sacks DB, Saenger AK. Establishment of community-based reference intervals for fructosamine, glycated albumin, and 1,5-anhydroglucitol. Clin Chem. 2018;64(5):843-50. https://doi.org/10.1373/clinchem.2017.285742 PMid:29436378 DOI: https://doi.org/10.1373/clinchem.2017.285742
Klimontov VV. Impact of glycemic variability on cardiovascular risk in diabetes. Kardiologiia. 2018;58(10):80-7. https://doi.org/10.18087/cardio.2018.10.10152 PMid:30359219 DOI: https://doi.org/10.18087/cardio.2018.10.10152
Kristensen SL, Rørth R, Jhund PS, Docherty KF, Sattar N, Preiss D, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with Type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776-85. https://doi.org/10.1016/S2213-8587(19)30249-9 PMid:31422062 DOI: https://doi.org/10.1016/S2213-8587(19)30249-9
de Wit-Verheggen VHW, van de Weijer T. Changes in cardiac metabolism in prediabetes. Biomolecules. 2021;11(11):1680. https://doi.org/10.3390/biom11111680 PMid:34827678 DOI: https://doi.org/10.3390/biom11111680
Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Blood Press. 2018;27(6):314-40. https://doi.org/10.1080/08037051.2018.1527177 PMid:30380928 DOI: https://doi.org/10.1080/08037051.2018.1527177
American Diabetes Association. Standards of medical care in diabetes-2018 abridged for primary care providers. Clin Diabetes. 2018;36(1):14-37. https://doi.org/10.2337/cd17-0119 PMid:29382975 DOI: https://doi.org/10.2337/cd17-0119
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Eur Heart J. 2012;33(20):2551-67. https://doi.org/10.1161/CIR.0b013e31826e1058 PMid:22923432 DOI: https://doi.org/10.1161/CIR.0b013e31826e1058
Ikeda N, Hara H, Hiroi Y. 1,5-Anhydro-D-glucitol predicts coronary artery disease prevalence and complexity. J Cardiol. 2014;64(4):297-301. https://doi.org/10.1016/j.jjcc.2014.02.014 PMid:24679905 DOI: https://doi.org/10.1016/j.jjcc.2014.02.014
Kim WJ, Park CY. 1,5-Anhydroglucitol in diabetes mellitus. Endocrine. 2013;43(1):33-40. https://doi.org/10.1007/s12020-012-9760-6 PMid:22847316 DOI: https://doi.org/10.1007/s12020-012-9760-6
Standl E, Schnell O, Ceriello A. Postprandial hyperglycemia and glycemic variability: Should we care? Diabetes Care. 2011;34(Suppl 2):S120-7. https://doi.org/10.2337/dc11-s206 PMid:21525442 DOI: https://doi.org/10.2337/dc11-s206
Kuroda M, Shinke T, Sakaguchi K, Otake H, Takaya T, Hirota Y, et al. Effect of daily glucose fluctuation on coronary plaque vulnerability in patients pre-treated with lipid-lowering therapy: A prospective observational study. JACC Cardiovasc Interv. 2015;8(6):800-11. https://doi.org/10.1016/j.jcin.2014.11.025 PMid:25999102 DOI: https://doi.org/10.1016/j.jcin.2014.11.025
Kishimoto M, Yamasaki Y, Kubota M, Arai K, Morishima T, Kawamori R, et al. 1,5-anhydro-D-glucitol evaluates daily glycemic excursions in well-controlled NIDDM. Diabetes Care. 1995;18(8):1156-9. https://doi.org/10.2337/diacare.18.8.1156 PMid:7587851 DOI: https://doi.org/10.2337/diacare.18.8.1156
Kahles F, Rückbeil MV, Mertens RW, Foldenauer AC, Arrivas MC, Moellmann J, et al. Glucagon-like peptide 1 levels predict cardiovascular risk in patients with acute myocardial infarction. Eur Heart J. 2020;41(7):882-9. https://doi.org/10.1093/eurheartj/ehz728 PMid:31620788 DOI: https://doi.org/10.1093/eurheartj/ehz728
Del Olmo-Garcia MI, Merino-Torres JF. GLP-1 receptor agonists and cardiovascular disease in patients with Type 2 diabetes. J Diabetes Res. 2018;2018:4020492. https://doi.org/10.1155/2018/4020492 PMid:29805980 DOI: https://doi.org/10.1155/2018/4020492
Li Y, Rosenblit PD. Glucagon-Like peptide-1 receptor agonists and cardiovascular risk reduction in Type 2 diabetes mellitus: Is it a class effect? Curr Cardiol Rep. 2018;20(11):113. https://doi.org/10.1007/s11886-018-1051-2 PMid:30259238 DOI: https://doi.org/10.1007/s11886-018-1051-2
Neeland IJ, Marso SP, Ayers CR, Lewis B, Oslica R, Francis W, et al. Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: A randomised, double-blind, placebo-controlled, clinical trial. Lancet Diabetes Endocrinol. 2021;9(9):595-605. https://doi.org/10.1016/S2213-8587(21)00179-0 PMid:34358471 DOI: https://doi.org/10.1016/S2213-8587(21)00179-0
Ramzy A, Kieffer TJ. Altered islet prohormone processing: A cause or consequence of diabetes? Physiol Rev. 2022;102(1):155-208. https://doi.org/10.1152/physrev.00008.2021 PMid:34280055 DOI: https://doi.org/10.1152/physrev.00008.2021
Miao Z, Alvarez M, Ko A, Bhagat Y, Rahmani E, Jew B, et al. The causal effect of obesity on prediabetes and insulin resistance reveals the important role of adipose tissue in insulin resistance. PLoS Genet. 2020;16(9):e1009018. https://doi.org/10.1371/journal.pgen.1009018 PMid:32925908 DOI: https://doi.org/10.1371/journal.pgen.1009018
Petersen JL, McGuire DK. Impaired glucose tolerance and impaired fasting glucose--a review of diagnosis, clinical implications and management. Diab Vasc Dis Res. 2005;2(1):9-15. https://doi.org/10.3132/dvdr.2005.007 PMid:16305067 DOI: https://doi.org/10.3132/dvdr.2005.007
Brannick B, Dagogo-Jack S. Prediabetes and cardiovascular disease: Pathophysiology and interventions for prevention and risk reduction. Endocrinol Metab Clin North Am. 2018;47(1):33-50. https://doi.org/10.1016/j.ecl.2017.10.001 PMid:29407055 DOI: https://doi.org/10.1016/j.ecl.2017.10.001
Chen J, Zhang W, Wu YQ, Chen H, Zhao JF. Correlations of acute myocardial infarction complicated by cerebral infarction with insulin resistance, adiponectin and HMGB1. Eur Rev Med Pharmacol Sci. 2019;23(10):4425-4431. https://doi.org/10.26355/eurrev_201905_17951 PMid:31173318
Wiebe N, Stenvinkel P, Tonelli M. Associations of chronic inflammation, insulin resistance, and severe obesity with mortality, myocardial infarction, cancer, and chronic pulmonary disease. JAMA Netw Open. 2019;2(8):e1910456. https://doi.org/10.1001/jamanetworkopen.2019.10456 PMid:31469399 DOI: https://doi.org/10.1001/jamanetworkopen.2019.10456
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 Dinara Sheryazdanova, Yelena Laryushina, Natalya Vassilyeva, Aygul Serikbaeva, Assel Alina, Maria Butyugina, Zauresh Tauesheva (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
